<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852239</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436A2106</org_study_id>
    <nct_id>NCT02852239</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment</brief_title>
  <official_title>A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral
      dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2016</start_date>
  <completion_date type="Anticipated">February 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel-group, open-label</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>The maximum (peak) observed plasma drug concentration after a single dose of dabrafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUClast)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>AUClast is the area under the curve calculated to the last quantifiable concentration point after a single dose of dabrafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUFinf)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>AUCinf is the area under the plasma concentration time curve extrapolated to infinity after a single dose of dabrafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic drug clearance (CL/F)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>Systemic clearance from plasma of dabrafenib after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>The time to reach maximum (peak) concentration of dabrafenib after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate (Lambda_z)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>Terminal elimination rate of dabrafenib after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>Elimination half-life of dabrafenib after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>The apparent volume of distribution during the terminal elimination phase of dabrafenib after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unchanged drug excreted in urine (Aet)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>The amount of unchanged dabrafenib excreted in urine after a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
    <description>Renal clearance of dabrafenib calculated using plasma AUC after a single dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Time of drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib through AE reports of subjects from drug administration through 30 days postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal lab values related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib through hematology and chemistry blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal blood pressure related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib by monitoring changes in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in electrocardiogram (ECG)</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib by monitoring changes in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal pulse rate related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib by monitoring changes in heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal respiratory rate related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
    <description>Assess the safety of a single dose of dabrafenib by monitoring changes in respiratory rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1 - Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal renal function defined as GFR â‰¥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Severe renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline can be enrolled in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - End stage renal disease (ESRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with end stage renal disease (ESRD), defined as GFR of &lt;15 mL/min at baseline can be enrolled in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>Single dose dabrafenib 100 mg</description>
    <arm_group_label>Group 1 - Normal renal function</arm_group_label>
    <arm_group_label>Group 2 - Severe renal function</arm_group_label>
    <arm_group_label>Group 3 - End stage renal disease (ESRD)</arm_group_label>
    <other_name>DRB436</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Females must be of non-childbearing potential or must have negative pregnancy results
             at screening

          -  Good health as determined by lack of clinically significant findings

          -  Subjects must have a BMI between 18.0 kg/m2 and 38.0 kg/m2, with a body weight of at
             least 50 kg and no more than 140 kg

          -  Vitals signs within normal range

          -  Laboratory values at screening within local normal ranges or considered non-clinically
             significant Additional criteria for renal impairment subjects

          -  Stable renal disease without evidence of renal progression in the past 28 days prior
             to dosing

          -  Additional criteria for healthy matched subjects:

          -  Matched to at least 1 renal impairment subject by race, age (+/-10 years), gender and
             weight (+/-10%)

          -  An absolute GFR of at least 90 ml/min

        Exclusion Criteria for all subjects:

          -  Significant acute illness within the two weeks prior to dosing

          -  History or current diagnosis of cardiac disease indicating significant risk such as
             uncontrolled or significant cardiac disease or clinically significant ECG
             abnormalities

          -  Subjects will be screened for drugs of abuse

          -  History of drug or alcohol abuse within 6 months prior to dosing or evidence of such
             abuse as indicated by laboratory values at screening or baseline.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs.

          -  History of malignancy of any organ system, treated or untreated, within 5 years,
             regardless of where there is recurrence or metastases.

          -  Use of drugs known to prolong the QT interval within 4 weeks prior to dosing and for
             the duration of the study.

          -  Use of drugs know to affect CYP3A4 and/or CYP2C8 including both (strong or moderate)
             inhibitors and inducers, within 7 days prior to dosing or during the current study are
             prohibited

        Other protocol-defined inclusion/exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>213-481-7142</phone>
    </contact>
    <investigator>
      <last_name>Michael Guice</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, LLC</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-668-4202</phone>
    </contact>
    <investigator>
      <last_name>Banji Awosika</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>856-753-7335</phone>
    </contact>
    <investigator>
      <last_name>Michael Hassman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates Oncology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-781-2514</phone>
    </contact>
    <investigator>
      <last_name>Wayne L Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal impairment</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Clinical pharmacology study</keyword>
  <keyword>DRB436</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>normal renal function</keyword>
  <keyword>impaired renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

